A. Meyer, Department of Psychology, Stony Brook University, Stony Brook, NY, USA. E-mail: firstname.lastname@example.org
The error-related negativity (ERN) is a negative deflection in the event-related potential that occurs approximately 50ms following the commission of an error at fronto-central electrode sites. Previous models suggest dopamine plays a role in the generation of the ERN. We recorded event-related potentials (ERPs) while 279 children aged 5–7 years completed a simple Go/No-Go task; the ERN was examined in relation to the dopamine D2 receptor (DRD2) and dopamine transporter (DAT1) genes. Results suggest an additive effect of the DRD2 and DAT1 genotype on ERN magnitude such that children with at least one DRD2 A1 allele and children with at least one DAT1 9 allele have an increased (i.e. more negative) ERN. These results provide further support for the involvement of dopamine in the generation of the ERN.
According to the reinforcement learning theory of the ERN, the ERN results from the disinhibition of the ACC by dopamine neurons when the basal ganglia evaluate ongoing actions as worse than expected (Holroyd & Coles 2002). Supporting the involvement of dopamine in the generation of the ERN, administration of a dopamine agonist (D-amphetamine) leads to an increased ERN amplitude (De Bruijn et al. 2004) and the administration of a dopamine antagonist (i.e. haloperidol) leads to a decreased ERN (De Bruijn et al. 2006; Zirnheld et al. 2004). Additionally, several studies have found that individuals with Parkinson's disease, which is characterized by dopamine depletion, have a diminished ERN (Jocham & Ullsperger 2009; Ito & Kitagawa 2006; Stemmer et al. 2004; Willemssen et al. 2008). Suggesting some specificity between dopamine and the ERN, one study found that the selective serotonin reuptake inhibitor paroxetine had no effect on ERN amplitude (De Bruijn et al. 2006).
In light of these data, it may be fruitful to examine associations between the ERN and genetic polymorphisms related to variation in dopamine. This study examined two dopamine genes: D2 dopamine receptor (DRD2) gene and dopamine transporter gene (DAT1 or SCL6A3).
The DRD2 gene located on chromosome 11q, encodes the D2 subtype of the dopamine receptor. The Taq1 A1 polymorphism (rs1870497) of the DRD2 gene has been related to reduced D2 dopamine receptor binding affinity (Noble 2003), and more specifically to lower dopamine receptor density in the striatum (Jonsson et al. 1999). An in vivo positron emission tomography (PET) study suggested that individuals with the A1 allele are characterized by a significant decrease in DRD2 receptor availability in the striatum relative to individuals homozygous for the A2 allele (Pohjalainen et al. 1998a) and a post-mortem study found fewer D2 receptors in the brains of individuals with the A1 allele. Importantly, evidence suggests that carriers of the A1 allele have upregulated synthesis of dopamine in the brain due to decreased autoreceptor function (Laakso et al. 2005). Based upon the pharmacological findings previously discussed, carriers of the A1 allele may exhibit an increased ERN due to increased availability of dopamine. In general, adults have fewer D2 receptors than children (Seeman et al. 1987) and women may have fewer D2 receptors in the striatum than men (Pohjalainen et al. 1998b). Studies of animals and humans have linked the DRD2 polymorphism to impaired social functioning and anxious and depressive symptoms (Hayden et al. 2010; Lawford et al. 2006; Schneier et al. 2000; Shively et al. 1997).
In adults, two previous studies have investigated the role of the DRD2 (Mueller et al. 2011) and DAT1 (Biehl et al. 2011) polymorphisms in the generation of the ERN, both finding no association. The ERN has recently begun to be examined in children, suggesting that although it may be slightly more posterior, it is both spatially and temporally similar to the ERN in adults (Brooker et al. 2011; Ladouceur et al. 2007; Meyer et al. 2012; Torpey et al. 2009) and has been shown to increase in magnitude with age (Davies et al. 2004; Torpey et al. 2011). Thus, both the ERN (Davies et al. 2004; Torpey et al. 2011) and dopamine systems (Fareri et al. 2008) are known to change across the lifespan, and therefore may relate to one another differently among children than in adults. In children, two previous studies of the same sample reported no independent association of DRD2 and DAT1 genotypes with the ERN (Althaus et al. 2009, 2010). However, the sample was comprised of 65 children, most of them with a diagnosis of either Pervasive Developmental Disorder or ADHD. No study to date has examined the relationship between these two dopamine genotypes and ERN in a large normative sample of children.
In this study, ERPs were recorded while 279 children aged 5–7 years completed a simple Go/No-Go task. Information about each child's dopamine genotypes (DRD2 and DAT1) was collected to investigate potential relationships between the ERN and dopamine-related gene polymorphisms. Given that the DRD2 A1 allele has been associated with an upregulation of dopamine and the DAT1 9 allele has been associated with increased activation of the ACC, we expected that children with the DRD2 A1 allele and children with the DAT1 9 allele would have larger (i. e., more negative) ERN amplitudes.
The sample included 279 children (124 female) from a suburban community. The original sample included 412 children. In this analysis 57 were excluded due to non-consent for genetic information and 3 were excluded because they carried a rare variant of the DAT1 gene. Because Olvet and Hajcak (2008) found that six or more error trials are needed for a stable ERN, data from 73 of 352 (20.74%) children in total were excluded from further analyses.
The mean age of the children was 6.10 years, SD = 0.43, range = 5.15–7.57 years at the time of the laboratory visit. The children were part of a larger study that involved an initial assessment approximately 3 years prior. Originally, potential participants were identified through a commercial mailing list. Eligible families were contacted by the Stony Brook University Center for Survey Research and had a child between 3 and 4 years of age, with no developmental disability or significant medical conditions, and at least one English-speaking biological parent. In the overall sample, 87.4% of the children were Caucasian, 69.3% had at least one parent who was a college graduate and 95.4% came from two-parent homes.
When participants came to the laboratory for the initial assessment, buccal cells were collected for genetic analysis by rubbing the inside of each child participant's cheek with two swabs. The Qiagen DNA Micro Kit (Qiagen, Valencia, CA, USA) was used to extract genomic DNA from buccal swab samples according to the manufacturer's instructions. Extracts were kept at 4°C when being analyzed, and were held at −80°C for long-term storage. Polymerase chain reaction (PCR) was carried out using the Applied Biosystems thermal cycler Gene Amp 9700 (Applied Biosystems, Foster City, CA, USA), and PCR products were separated on 6% polyacrylamide gels, stained with ethidium bromide, and visualized and documented by a UV imaging system (BioRad Labs, Mississauga, Ontario, Canada).
For the detection of the DRD2 Taq1A polymorphism, oligonucleotide primers 5′-CACGGCTGGCCAAGTTGTCTA-3′ (forward) and 5′-CACCTTCCTGAGTGTCATCAA-3′ (reverse) were used to amplify a 300-bp region flanking the Taq1A site (Grandy et al. 1993). The PCR conditions used were initial denaturation for 5 min at 95°C followed by 30 cycles of 30 seconds denaturation at 94°C, 30 seconds annealing at 58°C, and 30 seconds extension at 72°C, followed by a 5 min final extension at 72°C. The amplicons were digested overnight with 1U of Taqα1 restriction enzyme (New England BioLabs, Ipswich, MA, USA). The A1 allele is uncut by the restriction enzyme, whereas the A2 allele generates 125 and 175 bp fragments. Of the 279 children who provided a DNA sample, 11children had the A1A1 homozygous genotype, 80 were heterozygous (A1A2) and 188 had the A2A2 homozygous genotype. These genotype frequencies are in Hardy–Weinberg equilibrium χ2(1)= 0.56, P = 0.45. All genotyping was performed by research technicians blind to other study data. Consistent with most published research, and considering the rarity of the A1A1 genotype, groups for data analysis were formed based on whether children had (N = 91) or did not have (N = 188) an A1 allele.
A 40 nucleotide VNTR polymorphism has been identified within the 3′ non-coding region of the DAT1 gene. Alleles of this VNTR sequence range from 3 to 13 repeats, but the 9-repeat and 10-repeat alleles are the most common (Palmatier et al. 1999). For this study, the primers used were 5′-TGTGGTGTAGGGAACGGCCTGAG-3′ (forward) and 5′-CTTCCTGGAGGTCACGG CTCAAGG-3′ (reverse). PCR conditions were as follows: 5 min initial denaturation at 95°C and 30 cycles of 30 seconds initial denaturation at 94°C, 45 seconds annealing at 67.5°C, 45 seconds extension at 72°C, followed by 5 min of final extension at 72°C. The 9-repeat and 10-repeat products yield a 440- and 480-bp fragment, respectively. Of those 279 children we were successfully able to genotype for the DAT1 allele, 138 of them were homozygous for the DAT1 10R allele, 24 of them were homozygous for the 9R allele, and 117 were 9R/10R heterozygous. These genotype frequencies are in Hardy–Weinberg equilibrium χ2(1) = 0.01, P = 0.92. Three of the children had an unusual variant (the 11R) and have been excluded from the analysis. Consistent with previous studies (Althaus et al. 2010), two groups were formed based on whether children were homozygous for the 10R allele (138 children) or carried at least one 9R allele (141 children). Additionally, the results of a chi-square test of independence suggest that the variants of the two genotypes (DRD2 and DAT1) are independent, χ2(1, N = 279) = 0.26, P = 0.61.
Task and materials
A Go/No-Go paradigm, described previously in Torpey et al. (2011), was administered using Presentation software (Neurobehavioral Systems, Inc., Albany, CA, USA). The stimuli were green equilateral triangles in four different orientations. There were a total of 240 trials, 60% of the triangles were vertically aligned and pointed up, 20% were vertically aligned and pointed down, 10% were tilted slightly to the left, and 10% were titled slightly to the right. Children were instructed to respond to upward-pointing triangles by pressing a button, and to withhold responses to all other stimuli.
A series of practice blocks were administered to ensure that the participant understood the various aspects of the task. After completing the practice blocks, children were instructed that for each block, they would earn one point for correct responses on Go trials and for withholding responses on No-Go trials. They were told that if they earned enough points, they could win up to $5.00. Speed of response was again emphasized to the children. Between each block, the experimenter told the participants how many points they earned and reminded the children of the task instructions, emphasizing response speed.
Data were acquired using the Active Two system (Biosemi, Amsterdam, The Netherlands). 32 Ag/AgCl-tipped electrodes arranged according to the American Electroencephalographic Society labeling system (1994) were used with a small amount of electrolyte (Signa Gel; Bio-Medical Instruments Inc., Warren, MI, USA) applied to the child's scalp at each electrode position. For more information on data acquisition, see Torpey et al. (2011).
Offline, all data processing was performed with Brain Vision Analyzer (Brain Products, Gilching, Germany). Electroencephalogram data was re-referenced to the nose, and high- and low-pass filtered at 1 and 30 Hz, respectively. From the continuous EEG, 1500 milliseconds segments were extracted beginning 500 milliseconds prior to correct and erroneous responses. ERP data were corrected for blinks and eye-movements using the method developed by Gratton, Coles, and Donchin (1983). Additional artifacts were rejected when any of the following criteria are met: a voltage step of more than 50 µV between data points, a voltage difference of 300 µV within a single trial or a voltage difference of less than 0.5 µV within 100 milliseconds intervals. Data were also visually inspected for any remaining artifacts. ERP averages were then created separately for each trial type (correct and error) and were baseline corrected by subtracting from each data point the average activity the −500 to −300 milliseconds window prior to the response. Trials were not included in ERP averages if the reaction time occurred outside of a 200–1300 milliseconds window.
The ERP and behavioral results in the full sample have been reported previously (Torpey et al. 2011). In this study, we focus on the impact of DRD2 and DAT1 genotype on the error-related negativity (ERN) and correct-related negativity (CRN), which were scored at Cz as the average voltage in the window from 0 to 100 milliseconds after the response, where error-related brain response was maximal (Torpey et al. 2011). The ERN can be calculated by averaging the error-trial waveform or by subtracting the correct-trial waveform from the error-trial waveform (i.e. ΔERN) (Pailing et al. 2002). The ERN on error trials alone likely includes processes common to both error and correct responses. By subtracting correct from error trials (ΔERN), processes common to both correct and error responses are removed, resulting in a measure of neural activity specific to errors. Thus, all analyses examined the CRN, ERN and ΔERN.
Behavioral measures included both the number of errors of commission and omission for each subject. Average reaction times (RTs) on error and correct trials were also calculated separately, as were RTs on correct trials that followed errors trials to evaluate post-error RT slowing. Trials were removed from all analyses if reaction times were faster than 200 milliseconds or slower than 1300 milliseconds.
Statistical analyses were conducted using SPSS (Version 17.0) General Linear Model software, with Greenhouse-Geisser correction applied to P values associated with multiple-df, repeated-measures comparisons when necessitated by violation of the assumption of sphericity. Analyses were structured with the goal of finding main effects as well as interactive or additive effects of child DRD2 and DAT1 genotypes on the ERN, CRN and ΔERN. Repeated measures analysis of variances (anovas) were conducted, with response type (i.e. CRN and ERN) as a within-subject variable and DRD2 and DAT1 genotypes as between-subjects variables. Follow-up one-way anovas were conducted to determine how each genotype specifically related to CRN, ERN and ΔERN. Additionally, hierarchical multiple regression analyses were performed to confirm that the effects of DRD2 and DAT1 were additive on ERN. A follow-up repeated measures anova was conducted with age, reaction time, and accuracy as covariates, followed by a mediation analysis. Finally, post hocanovas were conducted to investigate the potential role of gender in the relationship between the dopamine genotypes and ERN.
Because of technical error, the behavioral data from six participants were lost; however, the ERP data for these subjects were included in the analyses. This left a total of 273 subjects that could be included in the behavioral analyses and 279 subjects included in the ERP and genetic analyses.
Performance measures in the overall sample, and as a function of DRD2 and DAT1 genotype, are presented in Table 1. Consistent with previous work, children were significantly faster on error trials than on correct go trials, t(1, 272) = 32.42, P < 0.001. Compared to the overall mean of correct trial reaction time, participants were slower to generate a correct response on trials that occurred after an error, t(1, 272) = 5.90, P < 0.001. However, there were no overall reaction time differences as a function of either DRD2 or DAT1 genotype, F1,269 = 0.02, P = 0.89, F1,269 = 2.90, P = 0.09, respectively; neither DRD2, F1,269 = 0.71, P = 0.40, nor DAT1, F1,269 = 0.46, P = 0.50, interacted with trial type to impact reaction time. However, there was a three-way interaction between trial type, DRD2, and DAT1, F1,269 = 4.56, P < 0.05.
Table 1. Means (SD) of behavioral measures (milliseconds), ERN, CRN and (ERN–CRN) amplitude (µV) at Cz for the entire sample and the genotypes
All children (N = 279)
DRD2 A1 (N = 91)
DRD2 A2/A2 (N = 188)
DAT1 10/10 (N = 138)
DAT1 9 (N = 141)
Errors of commission
Errors of omission
As depicted in Fig. 3, post-hoc t-tests suggested that within the DRD2 A1 group, children who were homozygous for DAT1 10/10, were slower on correct trials than children with a DAT1 9 allele, t(1, 88) = −2.65, P < 0.01. Within the DRD2 A1 group, reaction time on error trials did not differ significantly between the two DAT1 genotypes, t(1, 88) = −1.01, P = 0.32. Within the DRD2 A2/A2 group, neither correct, t(1, 181) = 0.36, P = 0.72, nor error reaction times, t(1, 181) = −.59, P = 0.56, differed significantly between the DAT1 groups.
Additionally, post-error slowing did not differ by DRD2 genotype, F1,272 = 0.64, P = 0.42, or by DAT1 genotype, F1,272 = 0.004, P = 0.95, and there were no significant two- or three-way interactions involving genotypes and post-error slowing (all ps > 0.1).
Overall, participants committed an average of 16.10, SD = 7.62, errors of commission and an average of 10.12, SD = 11.05, errors of omission, out of a total of 240 trials. Children with at least one DAT1 9 allele made significantly fewer errors of commission and fewer errors of omission than children who were homozygous for the DAT1 10 allele, F1,272 = 4.08, P < 0.05 and F1,272 = 4.75, P < 0.05, respectively. All other effects and interactions did not reach significance (all ps > 0.1).
Means and standard deviations of ERN, CRN and ΔERN as a function of genotype are included in Table 2, response-locked waveforms at Cz for ERN and CRN for each genotype are included in Figs 1 and 2. The ERP response was more negative following errors than correct responses, F1,275 = 222.25, P < 0.001. There was no overall difference in brain activity as a function of the DRD2 or DAT1 genotypes, F1,275 = 2.98, P < 0.09, and F1,275 = 0.51, P = 0.48, respectively. However, the effect of trial type was qualified by a significant interaction with DRD2 genotype, F1,275 = 6.37, P < 0.01. Children with at least one DRD2 A1 allele had a larger (i.e. more negative) ΔERN than children who were homozygous for the DRD2 A2 allele, F1,277 = 6.67, P < .01. This effect was driven by the effect of DRD2 genotype on the ERN, F1,277 = 6.11, P < 0.01 such that children carrying at least one DRD2 A1 allele had a significantly larger (i.e. more negative) ERN than children carrying the DRD2 A2 allele (homozygous for A2). Children did not differ in CRN between the two DRD2 genotypes, F1,277 = 0.072, P = 0.79.
Table 2. Overall and Incremental results from hierarchical regression analysis of genotype predicting ERPs at Cz
Step 1: DRD2
Step 2: DAT1
Step 1: DRD2
Step 2: DAT1
In addition, the difference between ERN and CRN also varied as a function of DAT1 genotype, F1,275 = 3.88, P < 0.05. Although neither the ERN nor the CRN differed between the two genotypes alone, F1,277 = 1.32, P = 0.25 and F1,277 = 2.95, P = 0.09, respectively, children with the DAT1 10 allele (homozygous for DAT1 10) had a significantly smaller (i.e. less negative) ΔERN than children with the DAT1 9 allele (with at least one DAT1 9 allele), F1,277 = 4.53, P < 0.05.
Neither the DAT1 by DRD2 two-way interaction, F1,275 = 3.62, P = 0.06, nor the three-way interaction between trial type, DAT1 genotype, and DRD2 genotype reached significance, F1,275 = 0.01, P = 0.92, suggesting two independent effects on error-related brain response related to the DAT1 and DRD2 genes. To investigate the possibility that the genotypes related differently to frontal/posterior electrode sites, a repeated-measures anova was conducted that suggested that the effect of trial type at Pz was also qualified by a significant interaction with the DRD2, F(1, 275) = 6.053, P < 0.01, and the DAT1 genotype, F(1, 275) = 6.46, P < 0.01. An additional repeated-measures anova suggested that the effect of trial type at Fz was qualified by a significant interaction with the DRD2 genotype, F(1,275) = 5.74, P < .05, but not the DAT1 genotype, F(1,275) = 2.51, P = 0.12.).
Hierarchical multiple regression analyses
To test for unique contribution of each genotype on the ERN, CRN and ΔERN we conducted separate hierarchical multiple regression analyses in which each of the ERPs were the dependent variables and potential predictor variable were the DRD2 and DAT1 genotypes. Results are shown in Table 2. As can be seen from the table, the additional variance accounted for in the ERPs by adding DAT1 as a predictor was significant in the case of ΔERN, R2 = 0.015, P < 0.05, although not in any of the other ERP measures. The variance in the difference score ΔERN accounted for by DRD2 alone was 2.4% and after DAT1 was added, the variance accounted for increased to a total of 3.8%, a significant increment. Thus, DAT1 significantly predicts the difference score ΔERN even after controlling for DRD2. This suggests an additive effect of the two genotypes. Overall and incremental results from the hierarchical regression analyses are included in Table 2.
A follow-up repeated measure anova suggested that when overall accuracy, reaction time (on error and correct trials), and age are added as covariates, the interaction between trial type and DRD2 remained significant, F1,265 = 6.07, P < 0.01, however, the effect of trial type was no longer qualified by the interaction with DAT1, F1,265 = 1.94, P = 0.17. Statistical analyses were conducted to test the potential mediation of accuracy on the relationship between DAT1 and ΔERN. The original beta for the relationship between DAT1 and ERN was 2.60, t(278) = 2.13, P < 0.05 and the beta for the relationship between DAT1 and accuracy was −4.75, t(272) = −2.73, P < 0.01. In the second regression analysis, the beta for accuracy predicting ERN was -.12, t(272) = −2.51, P < 0.01 and the beta for DAT1 predicting ERN was reduced to 2.03, t(272) = 1.63, P = 0.12. This reduction was significant; Sobel's test Z = 1.85, P < 0.05 (Fig. 3).
A follow-up repeated measure anova suggested that when gender was added as a covariate, it did not result in a significant interaction with ERN, F1,274 = 0.16, P = 0.69, and the interaction of DRD2 and ERN, F1,274 = 6.35, P < 0.01, and DAT1 and ERN, F1,274 = 3.99, P < 0.05, remained significant. However, a previous study has suggested that males and females differ in DRD2 binding in the striatum (Pohjalainen et al. 1998b) so further post hoc analyses were completed by dividing the sample into males and females. In males, the effect of trial type was not significantly qualified by an interaction with DRD2 genotype, F1,155 = 0.88, P = 0.35. However, in females there was a significant interaction of trial type with DRD2 genotype, F1,123 = 7.20, P < 0.01, such that females with the DRD2 A1 allele had a significantly more negative ERN, M = −3.67, SD = 7.53, than females without the DRD2 A1 allele, M = 1.01, SD = 11.04.
The results of this study suggest that there is an additive effect of the DRD2 and DAT1 genotype on ERN magnitude such that children with at least one DRD2 A1 allele and children with at least one DAT1 9 allele have an increased (i.e. more negative) ERN. This finding fits with the notion that the ERN is related to a reduction in dopaminergic activity seen on error trials when an expected reward is not delivered (Holroyd & Coles 2002).
Studies have suggested that the generation of the CRN may be due to error processing during correct trials (Coles et al. 2001); for instance, there is an increase in CRN amplitude as a function of subjectively rated inaccuracy on correct trials (Scheffers & Coles 2000). Although the children with the DAT1 9 allele did display a larger (i.e. more negative) ERN on error trials, they were also characterized by a smaller (i.e. less negative) CRN on correct trials – and better performance overall. It could be that these children were more accurate in judging when they had actually made an error and thus had a smaller CRN and larger ERN. This increased performance could be due to enhanced perceptual or attentional abilities. In fact, the DAT1 10/10 allele has previously been associated with attention deficit hyperactivity disorder (Faraone et al. 2005; Thapar et al. 2005), and decreased selective attention and response inhibition (Cornish et al. 2005).
Additionally, children with the DAT1 9 allele committed fewer errors of commission and omission, and within the DRD2 A1 group, children with the DAT1 9 allele were faster on correct trials. In this sample, the magnitude of ΔERN was previously related to better performance, indicated by greater accuracy, more correct No-Go trials and fewer errors of commission and omission (Torpey et al. 2011). And, previous studies have consistently found that ERN amplitude is increased when people make fewer errors (Amodio et al. 2008; Hajcak et al. 2003b). Additional statistical analyses were consistent with the hypothesis that increased accuracy may have driven the relationship observed between the DAT1 9 allele and increased ΔERN.
Overall, these findings fit with a previous study suggesting that children with the short variant of the 5-HTTLPR gene and also with a DRD2 A1 allele had a larger ERN (Althaus et al. 2009). While previous investigations of the relationship between the DAT1 genotype and ERN did not find a significant independent effect, this may have been due to a small sample size or in the study examining adults, age-related changes in dopamine transporter density (Althaus et al. 2010; Biehl et al. 2011). In fact, a previous study suggests that dopamine transporter density declines with age in a linear manner (Innis et al. 2002). It is important to note that one study found an association in adults with the DRD2 A1 allele and a reduced negative feedback-related fMRI signal in the rostral cingulate zone (Klein et al. 2007). However, this study included only male participants and it has been suggested that females may have a lower DRD2 binding affinity (Pohjalainen et al. 1998b). Follow-up analyses in our sample suggested that the relationship between the DRD2 A1 allele and ERN was only apparent in females. It may be that females have fewer D2 receptors and that females with the DRD2 A1 allele have even fewer receptors, contributing to a larger ERN. Future studies should investigate the possibility that the relationship between the DRD2 genotype and ERN may vary depending on gender.
In a previous paper, we reported a significant relationship between the DRD2 A1 allele and anxious symptoms emerging around age 3 (Hayden et al. 2010). A tentative possibility is that one mechanism through which the DRD2 A1 allele relates to enhanced anxiety in young children is by increased error monitoring related to fewer D2 receptors in the striatum. However, more research in this area is needed to substantiate this. Traditionally, the DRD2 A1 allele has been studied in adults in relationship to substance abuse (Dick & Foroud 2003) and a recent study suggests that an increased ERN is found in alcohol-dependent patients, especially those with comorbid anxiety disorders (Schellekens et al. 2010). Additionally, some evidence suggests anxiety may be a risk factor for the development of substance abuse problems (Cimander et al. 2001; Grant et al. 2004; Sartor et al. 2007). It is possible that the DRD2 A1 allele is related to an underlying liability to anxiety in childhood that transitions into a substance abuse trajectory by adulthood.
It is also important to note that the relationships observed between the two dopamine genes and ERN were found in a sample of young children. Indeed, the amplitude of the ERN increases with age (Davies et al. 2004; Torpey et al. 2011), D2 receptor expression in the striatum increases in childhood until age 5 and then decreases into adulthood (Seeman et al. 1987), and dopamine transporter density declines with age (Innis et al. 2002). Taken together, it is possible that the relationships observed between dopamine genotypes and ERN may vary as a function of age. Additionally, it is possible that genetic variants may have different functional consequences across development (Wahlstrom et al. 2007). Limited research has been done on this topic for the DRD2 and DAT1 genotypes, therefore generalizing research in children to adults and vice versa must be done cautiously. Prospective studies on the relationship of dopamine genes and ERN across development are needed to clarify this and also shed light on the hypothesized causal relationship between the genotypes and ERN. We are currently investigating this issue in ongoing and longitudinal studies.
This study is the first to find independent effects of two dopamine genes on ERN. This finding supports the reinforcement learning theory that suggests the ERN is related to a reduction in dopaminergic activity seen on error trials when an expected reward signal is not delivered (Holroyd & Coles 2002). Additionally, the association between candidate genes and the ERN may provide a potential mechanism through which the DRD2 and DAT1 genotypes relate to clinical phenotypes. Future research in adolescents and adults is needed to investigate the association of other dopamine genes (specifically: Dopamine receptor D4 and Catechol-O-methyltransferase) and error-related neural activity, and how dopamine-mediated error-related brain activity relates to clinical disorders across development.